11-Oct-2024
No headlines found.
Business Wire (Tue, 17-Sep 8:00 AM ET)
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PRNewswire (Wed, 4-Sep 6:50 AM ET)
PRNewswire (Tue, 3-Sep 6:50 AM ET)
Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results
PRNewswire (Wed, 14-Aug 6:50 AM ET)
PRNewswire (Wed, 7-Aug 6:50 AM ET)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Protalix Biotherapeutics (De) trades on the AMEX stock market under the symbol PLX.
As of October 11, 2024, PLX stock price climbed to $1.08 with 287,426 million shares trading.
PLX has a beta of 0.90, meaning it tends to be less sensitive to market movements. PLX has a correlation of 0.04 to the broad based SPY ETF.
PLX has a market cap of $79.43 million. This is considered a Micro Cap stock.
Last quarter Protalix Biotherapeutics (De) reported $13 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $974,000 and missed earnings estimates by -$.05.
In the last 3 years, PLX traded as high as $3.55 and as low as $.70.
The top ETF exchange traded funds that PLX belongs to (by Net Assets): IWC.
PLX has underperformed the market in the last year with a return of -30.3%, while the SPY ETF gained +34.4%. In the last 3 month period, PLX fell short of the market, returning -5.3%, while SPY returned +4.5%. However, in the most recent 2 weeks PLX has outperformed the stock market by returning +2.9%, while SPY returned +1.4%.
PLX support price is $.97 and resistance is $1.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLX shares will trade within this expected range on the day.